( December 17, 2012) -- The settlement of an antitrust action has put the acquisition of Actavis Inc. by Watson Pharmaceuticals back on track with a $5.9 billion price tag. According to the complaint filed with the proposed settlement last October, a deal consummated as planned would have imperiled competition between the two companies and reduced competition overall for a variety of medications that treat conditions ranging from hypertension and diabetes to anxiety and attention deficit hyperactivity disorder (ADHD)....